Thomas LaFramboise
Thomas LaFramboise
Unknown affiliation
Verified email at
Cited by
Cited by
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Z Zhang, JC Lee, L Lin, V Olivas, V Au, T LaFramboise, M Abdel-Rahman, ...
Nature genetics 44 (8), 852-860, 2012
High-throughput oncogene mutation profiling in human cancer
RK Thomas, AC Baker, RM DeBiasi, W Winckler, T LaFramboise, WM Lin, ...
Nature genetics 39 (3), 347-351, 2007
Single nucleotide polymorphism arrays: a decade of biological, computational and technological advances
T LaFramboise
Nucleic acids research 37 (13), 4181-4193, 2009
Dynamics of clonal evolution in myelodysplastic syndromes
H Makishima, T Yoshizato, K Yoshida, MA Sekeres, T Radivoyevitch, ...
Nature genetics 49 (2), 204-212, 2017
Dynamics of clonal evolution in myelodysplastic syndromes
H Makishima, T Yoshizato, K Yoshida, MA Sekeres, T Radivoyevitch, ...
Nature genetics 49 (2), 204-212, 2017
Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing
RK Thomas, E Nickerson, JF Simons, PA Jänne, T Tengs, Y Yuza, ...
Nature medicine 12 (7), 852-855, 2006
Integrative eQTL-based analyses reveal the biology of breast cancer risk loci
Q Li, JH Seo, B Stranger, A McKenna, I Pe’Er, T LaFramboise, M Brown, ...
Cell 152 (3), 633-641, 2013
Epigenomic enhancer profiling defines a signature of colon cancer
B Akhtar-Zaidi, R Cowper-Sal· lari, O Corradin, A Saiakhova, CF Bartels, ...
Science 336 (6082), 736-739, 2012
Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis
X Zhao, BA Weir, T LaFramboise, M Lin, R Beroukhim, L Garraway, ...
Cancer research 65 (13), 5561-5570, 2005
Comparative analysis of algorithms for next-generation sequencing read alignment
M Ruffalo, T LaFramboise, M Koyutürk
Bioinformatics 27 (20), 2790-2796, 2011
Predicting drug susceptibility of non–small cell lung cancers based on genetic lesions
ML Sos, K Michel, T Zander, J Weiss, P Frommolt, M Peifer, D Li, R Ullrich, ...
The Journal of clinical investigation 119 (6), 1727-1740, 2009
CHD7 targets active gene enhancer elements to modulate ES cell-specific gene expression
MP Schnetz, L Handoko, B Akhtar-Zaidi, CF Bartels, CF Pereira, ...
PLoS genetics 6 (7), e1001023, 2010
Genomic distribution of CHD7 on chromatin tracks H3K4 methylation patterns
MP Schnetz, CF Bartels, K Shastri, D Balasubramanian, GE Zentner, ...
Genome research 19 (4), 590-601, 2009
Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer
Y Hao, Y Samuels, Q Li, D Krokowski, BJ Guan, C Wang, Z Jin, B Dong, ...
Nature communications 7 (1), 11971, 2016
Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells
Z Zhang, S Kobayashi, AC Borczuk, RS Leidner, T LaFramboise, ...
Carcinogenesis 31 (4), 577-586, 2010
The tumor suppressor Cdc73 functionally associates with CPSF and CstF 3′ mRNA processing factors
O Rozenblatt-Rosen, T Nagaike, JM Francis, S Kaneko, KA Glatt, ...
Proceedings of the National Academy of Sciences 106 (3), 755-760, 2009
Identifying DNA methylation biomarkers for non-endoscopic detection of Barrett’s esophagus
HR Moinova, T LaFramboise, JD Lutterbaugh, AK Chandar, J Dumot, ...
Science translational medicine 10 (424), eaao5848, 2018
Allele-specific amplification in cancer revealed by SNP array analysis
T LaFramboise, BA Weir, X Zhao, R Beroukhim, C Li, D Harrington, ...
PLoS Computational Biology 1 (6), e65, 2005
The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272
Y Minami, T Shimamura, K Shah, T LaFramboise, KA Glatt, E Liniker, ...
Oncogene 26 (34), 5023-5027, 2007
Epitope tagging of endogenous proteins for genome-wide ChIP-chip studies
X Zhang, C Guo, Y Chen, HP Shulha, MP Schnetz, T LaFramboise, ...
Nature methods 5 (2), 163-165, 2008
The system can't perform the operation now. Try again later.
Articles 1–20